CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe

被引:0
|
作者
R. Paul Duffin
Michael Delbuono
Kylie Nishioka
Paul Shabram
Amish A. Patel
机构
[1] Emergent BioSolutions,
[2] Inc.,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
CVD 103-HgR live, attenuated oral cholera vaccine strain is indicated for single dose immunization against Vibrio cholerae, the causative agent for cholera. The vaccine packets containing buffer powder and lyophilized CVD 103-HgR are reconstituted in water and consumed. Studies were performed to explore the viability of CVD 103-HgR in drinking waters from common sources. CVD 103-HgR vaccine was reconstituted in bottled and tap waters from the United States and Europe, and viability was measured via colony forming units assay. Chemical analysis of select water samples was used to identify chemicals that have a negative effect on CVD 103-HgR viability. CVD 103-HgR titers were stable in all bottled waters tested, including purified bottled water, bottled spring water, and sparkling waters. However, tap water from certain cities in the US and Europe affected viability and are not compatible with vaccine. Water chemistry revealed that these tap waters contained copper, likely leached from copper plumbing. These studies give high confidence in the stability of CVD 103-HgR reconstituted in a variety of bottled waters. Waters containing copper, including tap water, should not be used to reconstitute CVD 103-HgR strain oral vaccine due to the common use of copper plumbing.
引用
收藏
相关论文
共 50 条
  • [21] Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial
    McCarty, James M.
    Lock, Michael D.
    Bennett, Sean
    Hunt, Kristin M.
    Simon, Jakub K.
    Gurwith, Marc
    [J]. VACCINE, 2019, 37 (11) : 1389 - 1397
  • [22] Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR
    Lagos, R
    Fasano, A
    Wasserman, SS
    Prado, V
    Martin, OS
    Abrego, P
    Losonsky, GA
    Alegria, S
    Levine, MM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05): : 1709 - 1712
  • [23] Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years
    McCarty, James M.
    Gierman, Emma C.
    Bedell, Lisa
    Lock, Michael D.
    Bennett, Sean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2020, 102 (01): : 48 - 57
  • [24] Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45
    McCarty, James M.
    Lock, Michael D.
    Hunt, Kristin M.
    Simon, Jakub K.
    Gurwith, Marc
    [J]. VACCINE, 2018, 36 (06) : 833 - 840
  • [25] Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area
    Richie, E
    Punjabi, NH
    Sidharta, Y
    Peetosutan, K
    Sukandar, M
    Wasserman, SS
    Lesmana, M
    Wangsasaputra, F
    Pandam, S
    Levine, MM
    O'Hanley, P
    Cryz, SJ
    Simanjuntak, CH
    [J]. VACCINE, 2000, 18 (22) : 2399 - 2410
  • [26] A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population
    Cookson, ST
    Stamboulian, D
    Demonte, J
    Quero, L
    DeArquiza, CM
    Aleman, A
    Lepetic, A
    Levine, MM
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (01) : 212 - 219
  • [27] Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States
    McCarty, James M.
    Cassie, David
    Bedell, Lisa
    Lock, Michael D.
    Bennett, Sean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 104 (03): : 861 - 865
  • [28] Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama
    Taylor, DN
    Sanchez, JL
    Castro, JM
    Lebron, C
    Parrado, CM
    Johnson, DE
    Tacket, CO
    Losonsky, GA
    Wasserman, SS
    Levine, MM
    Cryz, SJ
    [J]. INFECTION AND IMMUNITY, 1999, 67 (04) : 2030 - 2034
  • [29] The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae
    Mayo-Smith, Leslie M.
    Simon, Jakub K.
    Chen, Wilbur H.
    Haney, Douglas
    Lock, Michael
    Lyon, Caroline E.
    Calderwood, Stephen B.
    Kirkpatrick, Beth D.
    Cohen, Mitchell
    Levine, Myron M.
    Gurwith, Marc
    Harris, Jason B.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2017, 24 (01)
  • [30] Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States
    McCarty, James M.
    Cassie, David
    Bedell, Lisa
    Lock, Michael D.
    Bennett, Sean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 104 (05): : 1758 - 1760